Danshen injection combined with clopidogrel can improve clinical efficacy in the treatment of coronary heart disease; regulate the levels of NO, thromboxane B2 (TXB2), and endothelin-1 (ET-1); promote endothelial function recovery; and have better therapeutic effects than using clopidogrel alone [5,6]. The gene discussed is EDN1; the disease is coronary artery disorder.